Conditions: Cystic Fibrosis
Keywords: cystic fibrosis inflammation pH EBC sputum biomarkers phosphodiesterase inhibitors
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 36
Healthy volunteers: no

Brief summary:
The purpose of this study is to determine whether sildenafil can decrease inflammation in CF lung disease.

Detailed description:
This study is an open-label study that examines the use of sildenafil (Revatio) in clinically stable patients with mild to moderate CF lung disease. The length of participation for each subject will be approximately 10 weeks, and will consist of a screening visit, a study visit for initiation of study drug if subject qualifies, interim visits to escalate drug dose, obtain drug levels, review concomitant medications and assess side effects, a visit at the end of the therapy period (to reassess inflammatory markers, laboratory studies and side effects,) and a follow-up assessment 2 weeks after subject completion.

Arms:
arm 1: All subjects will receive oral sildenafil three times per day during the study. Study endpoints will be measured before the treatment period and at the end of the treatment period.

Interventions: intervention 1: sildenafil
Intervention descriptions: intervention 1: Sildenafil will be given 20mg po tid for 1 week, and then will be give 40mg po tid for 5 weeks.

Protocol document: